PDCD1 and non-small cell lung carcinoma: Camrelizumab is a humanized high-affinity IgG4-kappa anti-PD-1 monoclonal antibody, which has been approved in combination with chemotherapy (carboplatin plus paclitaxel or pemetrexed) for the first-line treatment of advanced non-small-cell lung cancer (NSCLC) (10, 11).